Lemme GLP-1 Daily Review: Does It Actually Work?
An evidence-based look at the viral "natural Ozempic" supplement: what is inside it, what the ingredient studies really found, the lawsuit over its claims, and whether it is worth the money.
Last Updated: June 2026 | Reading Time: 11 minutes | Bottom line: a low-risk supplement with modest blood-sugar support and weak weight-loss evidence, not a substitute for a GLP-1 medication.
What Is Lemme GLP-1 Daily?
Lemme GLP-1 Daily (more recently marketed as Lemme Reset) is a dietary supplement from Lemme, the wellness brand founded by Kourtney Kardashian Barker. It launched in September 2024 and rode the GLP-1 wave hard, positioned as a "natural" way to support your body's own GLP-1 production. It sold out quickly and became one of the most-searched supplement products of the year.
The marketing leans on the same hormone that makes Ozempic and Wegovy work: GLP-1 (glucagon-like peptide-1), a gut hormone that curbs appetite, slows gastric emptying, and steadies blood sugar. The crucial difference, covered in detail below, is that this product contains no GLP-1 and no drug. It is a capsule of plant extracts that may nudge your own GLP-1 upward by a small amount. For the full picture of how the hormone works, see our natural GLP-1 guide.
What Is in It: The Three Key Ingredients
The formula is built on three branded, patented extracts. Each has some human research behind it, which is more than most "GLP-1 booster" supplements can say. The honest caveat is that the evidence applies to the individual ingredients at studied doses, not to this finished combination, which has not been clinically tested as a product.
Eriomin (lemon extract, standardized to 70% eriocitrin)
This is the headline ingredient. In a 12-week randomized trial of people with prediabetes, Eriomin raised GLP-1 by about 17% and lowered fasting blood glucose by roughly 5% versus placebo. That is a real, measurable metabolic effect. The asterisk: the same study found no significant change in body weight, BMI, fat mass, or lean mass. So Eriomin's strongest evidence is for glucose and GLP-1 signaling, not for weight loss.
Morosil (red orange fruit extract)
Morosil has small trials suggesting modest reductions in body weight and waist circumference over 12 weeks, often in the range of a few pounds. The effect sizes are small and the studies are limited, but it is one of the better-studied citrus extracts in the weight-management space.
Supresa (saffron extract)
Saffron extracts have been studied mostly for snacking behavior, appetite, and mood rather than scale weight. The plausible benefit here is fewer compulsive snacks, which can indirectly help intake. It is not a weight-loss agent on its own.
Does Lemme GLP-1 Actually Work?
Here is the part the marketing glosses over. The 17% GLP-1 increase that gets quoted comes from a study where participants did not lose weight. A 17% bump in a hormone sounds impressive until you compare it to what a GLP-1 drug does: medications like semaglutide and tirzepatide deliver receptor activation many times stronger than anything a food extract produces, which is why they drive 15-23% body-weight loss in trials and a supplement does not.
A fair summary of the evidence: Lemme GLP-1 may offer modest support for blood-sugar stability and appetite for some people. It is not going to produce the kind of weight loss the "natural Ozempic" framing implies. If you go in expecting a gentle nutritional nudge, you may be satisfied. If you go in expecting drug-like results, you will be disappointed. For supplements with a similar evidence problem, compare our take on berberine for weight loss and the broader GLP-1 supplements roundup.
The Class-Action Lawsuit Over Its Claims
In 2025, a proposed class-action lawsuit challenged the marketing behind Lemme GLP-1 / Lemme Reset, arguing that branding a supplement "GLP-1" and tying it to weight management overstates what plant extracts can do and misleads consumers into thinking it works like the prescription drugs. Whatever the legal outcome, the case lands on the exact tension in this product: the distance between the marketing and the published data. It is a useful reason to read the ingredient studies yourself before buying.
What It Costs and the Value Question
Lemme GLP-1 Daily runs roughly $60-$72 for a one-month supply, cheaper on subscription. Call it $700-$850 a year. That is a lot for a supplement whose strongest documented effect is a blood-glucose nudge.
Two cheaper comparisons worth weighing. First, the active ingredients exist as standalone generic extracts (eriocitrin, red-orange extract, saffron) at a fraction of the bundled price. Second, the lifestyle levers that raise GLP-1, more protein and soluble fiber, regular exercise, and adequate sleep, cost nothing and have better evidence than any capsule. Our GLP-1 foods guide covers those. And if your real goal is significant weight loss, that annual budget overlaps with the cost of compounded semaglutide or compounded tirzepatide, which actually produce the results people are chasing, with a prescription and medical oversight.
Lemme GLP-1 vs Actual GLP-1 Medications
The single most important thing to understand: a supplement and a drug are not the same category, and no marketing language changes that.
| Factor | Lemme GLP-1 (supplement) | Semaglutide / Tirzepatide (drug) |
|---|---|---|
| Mechanism | May raise your own GLP-1 modestly | Directly activates GLP-1 receptors |
| Typical weight loss | Minimal to none in studies | 15-23% of body weight in trials |
| Prescription | No | Yes |
| Side effects | Mild, rare | Nausea, GI upset, more |
| Monthly cost | ~$60-$72 | ~$150-$500 compounded |
If you are trying to decide between options, our guide on which GLP-1 is best for weight loss and the semaglutide vs tirzepatide comparison are better starting points than any supplement.
Who Should and Should Not Buy It
Reasonable fit: someone with mild metabolic goals who wants a low-risk daily supplement, values better blood-sugar stability and slightly improved satiety, and holds realistic expectations. If that is you, the safety profile is clean and the downside is mostly cost.
Poor fit: anyone who needs real weight loss, who is managing obesity or type 2 diabetes, or who is comparing this to a prescription GLP-1 and expecting comparable results. For that goal, the honest answer is that a supplement cannot close the gap with a drug, and spending $700+ a year on it is unlikely to pay off. Look instead at GLP-1 medication options and discuss them with a clinician.
Safety and Interactions
For healthy adults, the lemon, red-orange, and saffron extracts in this formula have good tolerability at studied doses. The main cautions: saffron at higher doses can cause mild GI effects and may interact with mood medications, so anyone on antidepressants should check with a clinician. Because the formula can affect blood sugar, people taking glucose-lowering medication should not stack it without medical advice, and pregnant or breastfeeding people should avoid it absent a doctor's sign-off. As with all supplements, efficacy is not FDA-reviewed and manufacturing standards differ from prescription drugs.
Frequently Asked Questions About Lemme GLP-1
No. Lemme GLP-1 Daily (also sold as Lemme Reset) contains no GLP-1 hormone, no semaglutide, and no GLP-1 receptor agonist drug. It is a plant-extract dietary supplement. The name refers to the claim that its ingredients may nudge your body's own GLP-1 production upward. That is a fundamentally different mechanism from Ozempic, Wegovy, or compounded semaglutide, which deliver a drug that directly activates GLP-1 receptors at pharmacological levels. If you are expecting a drug-like appetite shutdown, this is not that.
The formula is built around three branded, patented plant extracts: Eriomin (a lemon extract standardized to 70% eriocitrin), Morosil (a red orange fruit extract), and Supresa (a saffron extract). Eriomin is the headline ingredient. A 12-week human study of Eriomin in people with prediabetes reported about a 17% increase in GLP-1 and roughly a 5% drop in blood glucose versus placebo. Morosil has small trials suggesting modest reductions in body weight and waist circumference. Supresa saffron has been studied for appetite and snacking behavior. The catch: these results come from the individual ingredients at specific doses, not from this combination product, which has not been tested as a finished formula.
The evidence for meaningful weight loss is weak. The Eriomin prediabetes study that gets cited for the 17% GLP-1 bump actually found no significant change in body weight, BMI, fat mass, or lean mass over 12 weeks. Morosil shows small effects on waist and weight in some trials, often a few pounds. Saffron mostly affects snacking and mood rather than scale weight. So the honest read is: this supplement may modestly support blood-sugar handling and appetite for some people, but it is not a weight-loss drug and the published data do not support the dramatic results the marketing implies. For comparison, GLP-1 medications produce 15-23% body-weight reductions in trials.
Yes. A proposed class-action lawsuit was filed in 2025 challenging the marketing claims behind Lemme GLP-1 / Lemme Reset, arguing that the "GLP-1" branding and weight-management messaging overstate what the supplement can do. The dispute centers on whether labeling a supplement "GLP-1" misleads consumers into thinking it works like the prescription drugs. This is worth knowing before you buy: the central question in the case is exactly the gap between the marketing and the clinical evidence.
Lemme GLP-1 Daily runs roughly $60-$72 for a one-month supply, with a lower price on subscription. Over a year that is around $700-$850. By contrast, the active ingredients sold generically (a standalone eriocitrin or red-orange extract, plus saffron) cost far less, and lifestyle changes that raise GLP-1 naturally, such as higher protein and soluble fiber, cost nothing. If your goal is real appetite control, that price buys a lot more of a GLP-1 medication through a compounding pharmacy in many cases, though that requires a prescription and carries its own risk profile.
They are not in the same category. Ozempic and compounded semaglutide are GLP-1 receptor agonist drugs that produce strong, reliable appetite suppression and 10-20%+ weight loss in most users, with real side effects (nausea, GI upset) and medical supervision. Lemme GLP-1 is a supplement that may slightly raise your own GLP-1 and help blood sugar, with mild or no effect on weight for most people and a clean safety profile. One is a medication; the other is a wellness product. If you want drug-level results, a supplement will disappoint you. If you want a low-risk nutritional nudge and realistic expectations, it may fit.
The ingredients (lemon, red orange, and saffron extracts) have good tolerability records at studied doses, and the supplement is generally considered low risk for healthy adults. Saffron at high doses can cause mild GI effects or interact with mood medications, so people on antidepressants should check with a clinician. As with any supplement, quality and dosing are not FDA-reviewed for efficacy, and supplements are not held to the manufacturing standards of prescription drugs. Pregnant or breastfeeding people and anyone on glucose-lowering medication should talk to a doctor first, since stacking blood-sugar effects matters.
It makes the most sense for someone with mild metabolic goals who wants a low-risk supplement and has realistic expectations: better blood-sugar stability, slightly improved satiety, and a daily habit, not double-digit weight loss. It is a poor fit for anyone who needs significant weight loss, who is treating obesity or type 2 diabetes, or who is comparing it head-to-head with a prescription GLP-1 and expecting similar results. For that group, the gap between a supplement and a drug is the whole story.
Want Results, Not Just a Nudge?
If your goal is real appetite control and weight loss, the evidence points to GLP-1 medications, not supplements. Start with a clear-eyed comparison of the actual options and their costs.
Compare GLP-1 Medication Options